Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)
Status:
Completed
Trial end date:
2021-02-03
Target enrollment:
Participant gender:
Summary
This clinical study was designed to evaluate the pharmacokinetics, safety and efficacy of
ligelizumab in children from 12 to < 18 years of age, with chronic spontaneous urticaria
(CSU). The participants were treated with ligelizumab as an add-on therapy to approved doses
of H1 antihistamines (H1AH) following the guideline on treatment of CSU.